|
Verici Dx PLC - Tennessee-based developer of clinical diagnostics for organ transplants - Confirms equity issue raises full target of £10.0 million from the sale of 28.6 million new shares at 35 pence each. The new shares represent 20% of Verici Dx's total beforehand. T
he offer was run by Singer Capital Markets. Verici Dx previously had said the funds will be used to accelerate the commercialisation of its two lead products, Clarava and Tuteva, and to continue the development of third product Protega. The Icahn School of Medicine at Mount Sinai, a hospital in New York, subscribed for 1.1 million of the new shares and now holds 18.4 million shares, a 13% stake.
Current stock price: 35.50p
12-month change: down 48%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
